Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
A crossover trial finds the Omnipod 5 Activity feature reduces insulin and blunts exercise glucose drops in type 1 diabetes, though hypoglycemia rates were unchanged. PICO summary and commentary.
A double-blind RCT finds nanocurcumin does not improve pain or neuropathy outcomes in diabetic peripheral neuropathy. PICO summary and expert commentary.
A randomized open-label pilot trial tested whether slower, flexible semaglutide titration reduces gastrointestinal dropout in type 2 diabetes versus the label regimen. PICO summary and expert commentary.
A secondary analysis of the DIAMANTE trial finds an adaptive texting intervention did not improve patient-provider communication in diabetes and depression. PICO summary and commentary.
A mechanistic randomized trial found empagliflozin reduced total-body norepinephrine turnover at 1 day and 12 weeks even as hepatic glucose production rose, with the two changes inversely correlated. PICO summary and expert commentary.
A small crossover trial found almond milk offered no postprandial glycaemic benefit over 2% cow milk in adults with type 2 diabetes, with the primary glucose endpoint null. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
